Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02478957
Other study ID # PA101-SM-02
Secondary ID
Status Completed
Phase Phase 2
First received June 19, 2015
Last updated September 27, 2016
Start date June 2015
Est. completion date June 2016

Study information

Verified date September 2016
Source Patara Pharma
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM).

The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.


Description:

The symptom scores for determining eligibility will be established during the 2-week Run-in Period using eDiary and the eligible patients will be randomly allocated in a 2:1 ratio to one of two treatment cohorts at the baseline visit.

In Cohort 1 (n=24), patients will receive inhaled 40 mg PA101 three times daily and inhaled placebo three times daily via eFlow for 6 weeks each in a double-blind, 2-period crossover fashion with a 4-week washout period between the treatment periods.

In Cohort 2 (n=12), patients will receive inhaled 40 mg PA101 three times daily via eFlow and oral cromolyn sodium 200 mg four times daily for 6 weeks each in an open label, 2-period crossover fashion with a 4-week washout period between the treatment periods.

Patients will be allowed to use the same daily doses of pre-randomization H1 and H2 antihistamines as well as the same daily doses of any other allowed medications during each treatment period.

Visits during each treatment period will occur at the baseline Visit, and at the end of Weeks 1, 2, 4, and 6.

Blood and urine samples will be collected to test for various biomarkers. In a subset of patients, additional clinical assessments of the skin will be performed and blood samples will be collected for pharmacokinetic assessments. Clinical safety assessments will be performed in all patients at the start and end of each treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date June 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Diagnosis of indolent systemic mastocytosis (ISM) according to the WHO criteria and the consensus proposal (2001)

- Experiencing at least one predefined qualifying symptom in at least two organ systems within 3 months of Screening despite the use of H1 and/or H2 antihistamines and other anti-mediator therapy

- Experiencing symptoms with a severity score of at least 4 for at least 7 out of 14 days during the Run-in period with at least one predefined qualifying symptom each from at least two organ systems, despite the use of H1 and/or H2 antihistamines and/or other anti-mediator therapy

- Willing and able to use an eDiary device daily for the duration of the study

- Completed at least 5 eDiary reports during each of two consecutive weeks of the Run-in period

- Willing and able to provide written informed consent prior to any study procedures

Exclusion Criteria:

- Advanced systemic mastocytosis (i.e., aggressive systemic mastocytosis [ASM], mast cell leukemia [MCL], or systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease [SM-AHNMD] )

- Current or recent history of clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that could put the patient at risk or compromise the quality of the study data as determined by the Investigator

- Use of oral cromolyn sodium within 6 weeks of Screening

- History of systemic corticosteroid, immunosuppressive, or anti-IgE monoclonal antibody therapy (e.g., omalizumab) within 6 months of Screening

- History of anaphylaxis requiring systemic treatment (i.e., corticosteroid or epinephrine) within 12 months of Screening

- Upper or lower respiratory tract infection within 4 weeks of Screening

- History of malignancy within the last 5 years, except basal cell carcinoma or cervix carcinoma in situ

- Major surgery within 6 months of Screening

- Current or recent history (within 12 months) of excessive use or abuse of alcohol

- Current or recent history (within 12 months) of abusing legal drugs or use of illegal drugs or substances

- Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study

- Participation in any other investigational drug study within 4 weeks of Screening

- History of hypersensitivity or intolerance to aerosol medications or cromolyn sodium

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
PA101
40 mg PA101 administered via inhalation three times daily for 6 weeks
Placebo
matching placebo administered via inhalation three times daily for 6 weeks

Locations

Country Name City State
France Hopital Necker - Enfants Malades Paris
Germany Charité - Universitätsmedizin Berlin Berlin
Germany Klinikum Darmstadt Darmstadt
Germany University Medical Center Mainz Mainz
Germany Technical University München Munich
Italy University of Salerno Salerno
Netherlands University Medical Center of Groningen Groningen
Spain Hospital Universitario de Fuenlabrada Madrid

Sponsors (1)

Lead Sponsor Collaborator
Patara Pharma

Countries where clinical trial is conducted

France,  Germany,  Italy,  Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall symptom score Mastocytosis Activity of Symptoms (MAS Plus) questionnaire for daily symptom score using eDiary 6 weeks No
Secondary Disease specific quality of life (QoL) Mastocytosis Impact Questionnaire (MIQ) for quality of life 6 weeks No
Secondary Patient Global Impression of Change (PGIC) scale 6 weeks No
See also
  Status Clinical Trial Phase
Completed NCT01333293 - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Phase 2/Phase 3
Completed NCT01481909 - Study on Mastocytosis for Rupatadine Treatment Phase 2/Phase 3
Recruiting NCT00044122 - Study of Factors Regulating Mast Cell Proliferation
Recruiting NCT06440148 - Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Not yet recruiting NCT05084872 - Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Phase 2/Phase 3
Terminated NCT01701843 - Cromoglicate in Mastocytosis Phase 2
Completed NCT00831974 - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Phase 2
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Completed NCT00006413 - Stem Cell Transplantation to Treat Systemic Mastocytosis Phase 2
Completed NCT00050193 - Cause and Natural Course of Pediatric-Onset Mastocytosis
Completed NCT02620254 - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT00001356 - Characteristics of Mast Cells in Mastocytosis N/A
Recruiting NCT06466889 - Mastocytosis Registry (of Zurich)
Recruiting NCT05186753 - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Not yet recruiting NCT06432556 - Study of Cellular Heterogeneity in Patients With Mastocytosis N/A
Completed NCT00336076 - Molecular Mechanisms and Diagnosis of Mastocytosis N/A